- Home
- » Tags
- » Brentuximab vedotin
Top View
- 1 Bosutinib Chronic Myeloid Leukaemia
- Factors Affecting the Pharmacology of Antibody–Drug Conjugates
- Immunoconjugates Advances in the Treatment of Hematologic
- Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma
- Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to 2 Improve the Therapeutic Index
- Brentuximab Vedotin in Combination with Rituximab, Cyclophosphamide
- Antibody-Drug Conjugates: Intellectual Property Considerations
- Non-Hodgkin Lymphoma Therapy Landscape
- Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
- A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab As Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression
- 2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
- The Oncology Market for Antibody–Drug Conjugates
- Clinical Roundtable Monograph
- Brentuximab Vedotin: a Novel Therapy for Refractory Lymphomas Editor By: Anthony S
- Mechanisms of Resistance to Monoclonal Antibodies (Mabs) in Lymphoid Malignancies
- ADCETRIS® (Brentuximab Vedotin) for Injection, for Intravenous Use • Peripheral Neuropathy: Monitor Patients for Neuropathy and Institute Initial U.S
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Specialty Injectables Prior Authorization List
- Brentuximab Vedotin
- Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma J
- Peripheral T-Cell Lymphoma
- Highlights in Lymphoma from the 2019 American Society of Clinical
- Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
- Biologic & Other Novel Agents
- Connecticare Commercial Connecticare Commercial J7192 Advate (Factor VIII)
- Molecular Features As Drug Targets and Antibody-Drug Conjugates for Therapy Hang-Ping Yao1,2*, Xiang-Min Tong3*, Rachel Hudson4,5 and Ming-Hai Wang1,2,4,5*
- Oncology Medications Policy (1403)
- Antibody–Drug Conjugates As Novel Anti-Cancer Chemotherapeutics
- Association Between Gvhd and Nivolumab in the FDA Adverse Event Reporting System
- Oncology Therapy for the Generalist
- CHMP Agenda of the 25-29 January 2021 Meeting
- Antibody–Drug Conjugates
- Brentuximab Vedotin Therapy for Cutaneous
- Mechanisms of Resistance to Antibody–Drug Conjugates Frank Loganzo, Matthew Sung, and Hans-Peter Gerber
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Immunotherapy and Target Therapy in Non-Hodgkin Lymphoma
- Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody–Drug Conjugates in Oncology
- Pan-Canadian Oncology Drug Review Initial Clinical Guidance Report
- Antibody–Drug Conjugates: Future Directions in Clinical And
- Targeted Approaches to T-Cell Lymphoma
- Phase II Trial of Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
- Characteristics of Non-Randomized Studies Using Comparisons with External Controls Submitted for Regulatory Approval in the Us and Europe: a Systematic Review
- Clinical Roundtable Monograph
- Brentuximab Vedotin
- Brentuximab-Rituximab for Relapsed/Refractory Classical
- Poent Promise
- Monoclonal Antibodies in Cancer Therapy
- Antibody–Drug Conjugates
- Multiplex LCMS Bioanalysis of Brentuximab Vedotin, Rituximab
- Brentuximab Vedotin) for Injection, for Intravenous Use • Anaphylaxis and Infusion Reactions: If an Infusion Reaction Occurs, Interrupt the Infusion
- Publication Agenda CHMP 07-10 December 2020
- QUICK FACTS FY 2020 AS of 12/31/2020: Other Solid Tumors
- Highlights in Lymphoma from the 2017 American Society of Clinical
- Regimen Reference Order – LYMP – Brentuximab Vedotin
- Systemic Therapy Update
- Antibody–Drug Conjugates: a Comprehensive Review Puregmaa Khongorzul1, Cai Jia Ling1, Farhan Ullah Khan2, Awais Ullah Ihsan3, and Juan Zhang1